DALLAS, Jan. 9, 2006 (PRIMEZONE) -- Reggie Sanchez, President of TwinTrader.com, announced Profile Coverage of The BioBalance Corp. (OTCBB:BBAL). Functioning as a specialty pharmaceutical company, The BioBalance Corp. is focused on the development of patented biotherapeutic agents for gastrointestinal disorders that are not adequately addressed by current therapies. These disorders include pouchitis, Irritable Bowel Syndrome (IBS), inflammatory bowel disease and diarrhea caused by antibiotics, chemotherapy or AIDS.
Reggie Sanchez and Scott Sanchez each spoke of The BioBalance Corp.:
Scott: "The BioBalance Corporation provides vital health solutions to a very real problem -- a problem that affects between 25 and 55 million people in the US." Reggie: "The BioBalance Corporation develops foods and pharmaceuticals to treat gastrointestinal diseases/disorders by restoring microbial balance to the digestive system." Scott: "I like The BioBalance Corporation's paradigm shift -- an 'alteration of the bacterial equilibrium.' Their products treat major mechanisms and root causes of GI diseases/disorders." Reggie: "Poorly treated gastrointestinal diseases represent a large market opportunity -- Irritable Bowel Syndrome alone constitutes a $3 billion market opportunity in the U.S."
To view the Twin Trader profile for The BioBalance Corp., please visit:
http://www.twintrader.com/profile/bbal/
About TwinTrader.com
TwinTrader.com features the best of the small cap and microcap markets. In addition to "offensive play" and "defensive plays" for members, TwinTrader features Profiles of key companies. Reggie Sanchez and Scott Sanchez, the Twin Traders, give their take on each and every profiled company.
To feature your publicly traded company in our alerts, or to discuss our complete services, please contact Reggie Sanchez by telephone at (214) 227-7559 or by e-mail at Reggie@TwinTrader.com. You may also contact Scott Sanchez by telephone at (214) 227-7560 or by e-mail at Scott@TwinTrader.com.
SAFE HARBOR STATEMENT: In addition to historical information, certain of the statements in the preceding paragraphs, particularly those anticipating future events, financial performance, business prospects and growth and operating strategies constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as anticipate, believe, estimate, expect, intend, predict, hope or similar expressions. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements, including, without limitation, satisfaction of regulatory and other approvals and conditions necessary to market PROBACTRIX(r), the Company's ability to implement its strategies and achieve its objectives and the risks and uncertainties described in reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation, the risk factors set forth and cautionary statements made in the Company's 2004 Annual Report on Form 10-K, as amended, its latest quarterly report on Form 10-Q and current reports on Form 8-K.
Disclosure: TwinTrader LLC was compensated $10,500 by a third party for profile coverage. TwinTrader LLC are not registered investment advisers or broker/dealers. TwinTrader LLC makes no recommendation that the purchase of securities of companies profiled in this Web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.